Osteosarcoma (OSA) represents the most common primary bone tumor in humans and pet dogs. Little progress has been made with regard to viable treatment options in the past three decades and patients presenting with metastatic disease continue to have a poor prognosis. Recent mouse studies have suggested that microRNA-34a (miR-34a) may have anti-tumor activities in human OSA models. Due to the conservation of microRNA across species, we hypothesized that a bioengineered miR-34a prodrug (tRNA/miR-34a) would have similar effects in canine OSA, providing a valuable preclinical model for development of this therapeutic modality. Using a panel of canine OSA cell lines, we found that tRNA/miR-34a reduced viability, clonogenic growth, and migration and invasion while increasing tumor cell apoptosis. Furthermore, canine OSA cells successfully process the tRNA/miR-34a into mature miR-34a which reduces expression of target proteins such as platelet derived growth factor receptor alpha (PDGFRα), Notch1 and vascular endothelial growth factor (VEGF). Additionally, our subcutaneous OSA xenograft model demonstrated in vivo tumor growth delay, increased necrosis and apoptosis by tRNA/miR-34a, and decreased cellular proliferation ability. Taken together, these data support that this novel microRNA-based therapy may possess clinical utility in a spontaneously-occurring large animal model of OSA, which can then serve to inform the clinical development of this therapy for human OSA patients.
Osteosarcoma remains the most common primary bone tumour in dogs with half of affected dogs unable to survive 1 year beyond diagnosis. New therapeutic options are needed to improve outcomes for this disease. Recent investigations into potential therapeutic targets have focused on cell surface molecules with little clear therapeutic benefit. Transcription factors and protein interactions represent underdeveloped areas of therapeutic drug development. We have utilized allosteric inhibitors of the core binding factor transcriptional complex, comprised of core binding factor beta (CBFβ) and RUNX2, in four canine osteosarcoma cell lines Active inhibitor compounds demonstrate anti‐tumour activities with concentrations demonstrated to be achievable in vivo while an inactive, structural analogue has no activity. We show that CBFβ inhibitors are capable of inducing apoptosis, inhibiting clonogenic cell growth, altering cell cycle progression and impeding migration and invasion in a cell line‐dependent manner. These effects coincide with a reduced interaction between RUNX2 and CBFβ and alterations in expression of RUNX2 target genes. We also show that addition of CBFβ inhibitors to the commonly used cytotoxic chemotherapeutic drugs doxorubicin and carboplatin leads to additive and/or synergistic anti‐proliferative effects in canine osteosarcoma cell lines. Taken together, we have identified the interaction between components of the core binding factor transcriptional complex, RUNX2 and CBFβ, as a potential novel therapeutic target in canine osteosarcoma and provide justification for further investigations into the anti‐tumour activities we describe here.
This study was undertaken to investigate the therapeutic effect of a genetically engineered, human pre-microRNA-34a prodrug in canine osteosarcoma (OS), validating a robust preclinical model for the development of this proposed agent in humans. Although osteosarcoma is the most prevalent primary bone tumor in children and young adults, the low overall incidence presents an obstacle to timely development and testing of new agents. However, the incidence of canine OS is nearly 12 times that in humans, providing a useful preclinical model with spontaneously occurring OS. Despite multimodal therapeutic protocols, up to 40% of human and 90% of dogs will not survive long-term. Therefore, there is a clear need to identify new therapeutic agents for OS treatment. MicroRNAs (miRs) are small, noncoding RNAs that control relevant cellular pathways in tumorigenesis. MiR-34a, a downstream component of the p53 tumor suppressor, is downregulated in OS tumors and its reduced expression linked to poor therapeutic response. Recent evidence in human OS cell lines has shown that a novel genetically engineered human tRNA/miR-34a prodrug has anti-tumor effects following intracellular processing into mature miR-34a. We transfected a panel of canine OS cell lines (D17, HMPOS, Abrams and Gracie) with the human tRNA/miR-34a prodrug and evaluated the downstream effects to validate canine OS as a preclinical model. We measured miR-34a levels following transfection using quantitative real-time PCR. Proliferation was assessed via bioreductive and clonogenic assays. Western blot and immunofluorescence microscopy were used to investigate miR-34a target protein expression. Caspase 3/7 activity and TUNEL staining were used to measure apoptotic effects. In vitro properties associated with metastatic ability were assessed via transwell migration and invasion assays using Boyden chambers. We found significant increases in mature miR-34a levels following transfection, indicating that canine cells effectively process the prodrug. Increased miR-34a was associated with reduced PDGFRα protein expression and dose- and time-dependent inhibition of proliferation. Compared to control and MSA-transfected cells, miR-34a significantly reduced clonogenic cell growth, increased caspase 3/7 activity, and increased TUNEL positivity. We also found a significant inhibition of canine OS cell migration and invasion following transfection with miR-34a prodrug. Taken together, our findings demonstrate the successful internalization and processing of human miR-34a prodrug by canine OS cells. The increased miR-34a levels produce the same anti-tumor effects seen in human OS cells. These results strongly supports the use of canine OS as a preclinical model for the development of this therapy in human OS. Citation Format: Fernando Alegre Guerra, Kellie Snider, Amanda Ormonde, Ai-Ming Yu, Luke Wittenburg. Canine osteosarcoma as a platform to investigate the therapeutic potential of a genetically engineered pre-microRNA prodrug in human osteosarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4406.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.